NASDAQ:QURE - uniQure Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $70.53
  • Forecasted Upside: 49.28 %
  • Number of Analysts: 16
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 13 Buy Ratings
  • 1 Strong Buy Ratings
$47.25
▲ +0.75 (1.61%)
1 month | 3 months | 12 months
Get New uniQure Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for QURE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for QURE

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$70.53
▲ +49.28% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for uniQure in the last 3 months. The average price target is $70.53, with a high forecast of $98.00 and a low forecast of $46.00. The average price target represents a 49.28% upside from the last price of $47.25.
Buy
The current consensus among 16 polled investment analysts is to buy stock in uniQure. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/9/2019
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/7/2019
  • 0 strong buy ratings
  • 13 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/6/2019
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/5/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/3/2020
  • 1 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/1/2020
  • 1 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/31/2020
  • 1 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/30/2020

Latest Recommendations

  • 1 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/24/2020HC WainwrightInitiated CoverageBuy$80.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
11/20/2020Credit Suisse GroupBoost Price TargetOutperform$76.00 ➝ $78.00High
i
11/11/2020Berenberg BankInitiated CoverageBuy$59.00High
i
11/9/2020Jefferies Financial GroupInitiated CoverageBuy$55.00Medium
i
11/4/2020Cantor FitzgeraldInitiated CoverageOverweight$65.00High
i
Rating by K. Kluska at Cantor Fitzgerald
10/28/2020MizuhoLower Price TargetNeutral$61.00 ➝ $46.00High
i
Rating by Difei Yang at Mizuho
10/22/2020Royal Bank of CanadaInitiated CoverageOutperform$61.00Medium
i
10/9/2020Cantor FitzgeraldReiterated RatingOverweightMedium
i
Rating by K. Kluska at Cantor Fitzgerald
8/24/2020Raymond JamesInitiated CoverageStrong-Buy$75.00High
i
8/11/2020Chardan CapitalReiterated RatingBuy$80.00Medium
i
Rating by Gbola Amusa at Chardan Capital
7/31/2020Credit Suisse GroupReiterated RatingBuy$76.00Low
i
7/31/2020Robert W. BairdUpgradeNeutral ➝ Outperform$58.00 ➝ $57.00Medium
i
Rating by Madhu Kumar at Robert W. Baird
7/14/2020MizuhoReiterated RatingHold$61.00Medium
i
Rating by Difei Yang at Mizuho
6/25/2020Chardan CapitalLower Price TargetBuy$105.00 ➝ $80.00High
i
Rating by Gbola Amusa at Chardan Capital
6/25/2020HC WainwrightLower Price TargetBuy$73.00 ➝ $64.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
6/25/2020Stifel NicolausLower Price TargetBuy$86.00 ➝ $78.00High
i
6/25/2020MizuhoReiterated RatingBuy ➝ Neutral$90.00 ➝ $61.00High
i
6/25/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$90.00 ➝ $56.00High
i
6/25/2020Robert W. BairdDowngradeOutperform ➝ Neutral$58.00High
i
6/19/2020HC WainwrightReiterated RatingBuy$73.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
5/29/2020Chardan CapitalReiterated RatingBuy$105.00Medium
i
Rating by Gbola Amusa at Chardan Capital
5/8/2020Chardan CapitalReiterated RatingBuy$105.00Low
i
Rating by Gbola Amusa at Chardan Capital
4/30/2020MizuhoReiterated RatingBuy$90.00Low
i
Rating by Difei Yang at Mizuho
3/3/2020HC WainwrightReiterated RatingBuy$73.00Medium
i
Rating by Debjit Chattopadhyay at HC Wainwright
3/3/2020Chardan CapitalLower Price TargetBuy$125.00 ➝ $105.00High
i
Rating by Gbola Amusa at Chardan Capital
2/10/2020HC WainwrightReiterated RatingBuy$73.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
1/29/2020Chardan CapitalReiterated RatingBuy$125.00Low
i
Rating by Gbola Amusa at Chardan Capital
1/23/2020Cantor FitzgeraldBoost Price TargetOverweight$94.00 ➝ $96.00Low
i
Rating by E. Merle at Cantor Fitzgerald
12/23/2019HC WainwrightReiterated RatingBuy$73.00N/A
i
Rating by Debjit Chattopadhyay at HC Wainwright
12/20/2019SunTrust BanksInitiated CoverageBuy$90.00Medium
i
Rating by Robyn Karnauskas at SunTrust Banks, Inc.
12/10/2019MizuhoReiterated RatingBuy$67.00 ➝ $90.00Medium
i
12/9/2019HC WainwrightReiterated RatingBuy$73.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
12/9/2019Chardan CapitalReiterated RatingBuy$125.00Medium
i
12/3/2019Piper Jaffray CompaniesReiterated RatingBuy$80.00Medium
i
Rating by Danielle Brill at Piper Jaffray Companies
12/3/2019CowenInitiated CoverageOutperformHigh
i
12/3/2019The Goldman Sachs GroupInitiated CoverageBuy$98.00High
i
11/5/2019Credit Suisse GroupInitiated CoverageOutperform$76.00High
i
10/17/2019Cantor FitzgeraldReiterated RatingOverweightLow
i
Rating by E. Merle at Cantor Fitzgerald
10/14/2019HC WainwrightReiterated RatingBuy$73.00Medium
i
Rating by Debjit Chattopadhyay at HC Wainwright
10/11/2019Stifel NicolausInitiated CoverageBuy$79.00Medium
i
9/24/2019Sanford C. BernsteinInitiated CoverageOutperform$73.00High
i
9/12/2019MizuhoInitiated CoverageBuy$67.00Low
i
9/3/2019HC WainwrightReiterated RatingBuyMedium
i
Rating by Debjit Chattopadhyay at HC Wainwright
9/3/2019Chardan CapitalReiterated RatingBuyMedium
i
7/29/2019GuggenheimDowngradeBuy ➝ NeutralMedium
i
7/8/2019HC WainwrightSet Price TargetBuy$73.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
7/8/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$81.00 ➝ $94.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
6/11/2019Janney Montgomery ScottReiterated RatingBuyHigh
i
Rating by Yun Zhong at Janney Montgomery Scott
5/10/2019Cantor FitzgeraldSet Price TargetBuy$81.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
5/7/2019SunTrust BanksBoost Price TargetBuy$76.00High
i
4/12/2019Piper Jaffray CompaniesInitiated CoverageOverweight$80.00Low
i
3/28/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$85.00Low
i
3/15/2019Wells Fargo & CompanyBoost Price TargetOutperform ➝ Outperform$65.00 ➝ $90.00Low
i
3/7/2019Cantor FitzgeraldReiterated RatingBuy$81.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
3/4/2019Chardan CapitalBoost Price TargetBuy$70.00 ➝ $100.00Low
i
2/28/2019Wells Fargo & CompanyBoost Price TargetOutperform$51.00 ➝ $65.00Low
i
2/26/2019HC WainwrightReiterated RatingBuyHigh
i
Rating by Debjit Chattopadhyay at HC Wainwright
2/26/2019SunTrust BanksBoost Price TargetBuy ➝ Positive$64.00High
i
2/25/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$68.00 ➝ $81.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
2/11/2019HC WainwrightReiterated RatingBuy ➝ Buy$60.00 ➝ $73.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
2/8/2019Cantor FitzgeraldReiterated RatingBuy$68.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
1/14/2019HC WainwrightSet Price TargetBuy$60.00Medium
i
Rating by Debjit Chattopadhyay at HC Wainwright
12/31/2018B. RileyInitiated CoverageBuy ➝ Buy$72.00 ➝ $72.00High
i
Rating by M. Kumar at B. Riley
12/17/2018GuggenheimInitiated CoverageBuy$35.00Low
i
Rating by Whitney Ijem at Guggenheim
12/4/2018HC WainwrightSet Price TargetBuy$60.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
12/3/2018Chardan CapitalReiterated RatingBuy$70.00Medium
i
11/26/2018HC WainwrightReiterated RatingBuy ➝ Buy$48.00 ➝ $60.00Medium
i
Rating by Debjit Chattopadhyay at HC Wainwright
11/16/2018B. RileyBoost Price TargetBuy ➝ Buy$50.00 ➝ $72.00Medium
i
Rating by M. Kumar at B. Riley
11/15/2018Cantor FitzgeraldReiterated RatingBuy$65.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
11/15/2018HC WainwrightSet Price TargetBuy$48.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
11/15/2018SVB LeerinkBoost Price TargetOutperform ➝ Positive$61.00 ➝ $76.00High
i
11/7/2018Chardan CapitalBoost Price TargetBuy$50.00 ➝ $70.00Low
i
11/7/2018HC WainwrightSet Price TargetBuy$48.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
10/19/2018HC WainwrightSet Price TargetBuy$48.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
10/18/2018Chardan CapitalReiterated RatingBuy$50.00High
i
Rating by G. Amusa at Chardan Capital
10/11/2018HC WainwrightSet Price TargetBuy$48.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
10/3/2018Cantor FitzgeraldSet Price TargetBuy$58.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
9/24/2018HC WainwrightBoost Price TargetBuy ➝ Buy$42.00 ➝ $48.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
8/23/2018HC WainwrightSet Price TargetBuy$42.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
8/23/2018Cantor FitzgeraldSet Price TargetBuy$58.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
8/13/2018CowenReiterated RatingBuyMedium
i
8/11/2018Cantor FitzgeraldSet Price TargetBuy$58.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
8/9/2018HC WainwrightSet Price TargetBuy$42.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
8/8/2018Janney Montgomery ScottReiterated RatingBuyLow
i
Rating by Yun Zhong at Janney Montgomery Scott
7/26/2018Cantor FitzgeraldInitiated CoverageOverweight$58.00High
i
Rating by E. Piros at Cantor Fitzgerald
7/17/2018HC WainwrightSet Price TargetBuy$42.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
6/29/2018HC WainwrightSet Price TargetBuy$42.00Medium
i
Rating by Debjit Chattopadhyay at HC Wainwright
6/27/2018B. RileyInitiated CoverageBuy$50.00High
i
Rating by M. Kumar at B. Riley
5/24/2018SunTrust BanksInitiated CoverageBuy$48.00High
i
5/22/2018HC WainwrightReiterated RatingBuy$42.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
5/16/2018Wells Fargo & CompanyInitiated CoverageOutperform$47.00Medium
i
5/7/2018SVB LeerinkReiterated RatingOutperform ➝ Outperform$26.00 ➝ $63.00Low
i
5/1/2018HC WainwrightSet Price TargetBuy$35.00Medium
i
Rating by Debjit Chattopadhyay at HC Wainwright
4/30/2018Chardan CapitalReiterated RatingBuyHigh
i
Rating by G. Amusa at Chardan Capital
4/23/2018HC WainwrightSet Price TargetBuy$35.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
3/20/2018Janney Montgomery ScottReiterated RatingBuy$30.00High
i
Rating by Yun Zhong at Janney Montgomery Scott
3/15/2018HC WainwrightSet Price TargetBuy$35.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
2/20/2018HC WainwrightSet Price TargetBuy$35.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
1/3/2018Janney Montgomery ScottInitiated CoverageBuy ➝ Buy$25.00Low
i
12/7/2017HC WainwrightSet Price TargetBuy$28.00High
i
Rating by D. Chattopadhyay at HC Wainwright
12/1/2017HC WainwrightInitiated CoverageBuy ➝ Buy$28.00High
i
Rating by D. Chattopadhyay at HC Wainwright
11/24/2017OppenheimerReiterated RatingHoldLow
i
11/7/2017SVB LeerinkBoost Price Target$19.00 ➝ $26.00N/A
i
11/7/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$22.00N/A
i
10/20/2017SVB LeerinkBoost Price TargetOutperform ➝ Outperform$17.00 ➝ $19.00N/A
i
7/23/2017Chardan CapitalSet Price TargetBuy$13.00High
i
Rating by Gbola Amusa at Chardan Capital
6/30/2017OppenheimerReiterated RatingOutperform$17.00Low
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
5/24/2017CowenReiterated RatingBuyMedium
i
5/16/2017OppenheimerSet Price TargetBuy$17.00Medium
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
4/12/2017Jefferies Financial GroupReiterated RatingHold$8.00Low
i
Rating by Eun Yang at Jefferies Financial Group Inc.
3/22/2017OppenheimerReiterated RatingBuyLow
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
1/30/2017Chardan CapitalReiterated RatingPositive$12.00N/A
i
12/25/2016OppenheimerSet Price TargetBuy$17.00N/A
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
12/6/2016WallachBeth CapitalLower Price TargetBuy$27.00 ➝ $15.00N/A
i
12/2/2016SVB LeerinkReiterated RatingOutperformN/A
i
Rating by J. Schwartz at SVB Leerink LLC
11/28/2016Jefferies Financial GroupDowngradeBuy ➝ Hold$28.00 ➝ $8.00N/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
11/21/2016Jefferies Financial GroupDowngradeBuy ➝ Hold$28.00 ➝ $8.00N/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
11/15/2016Piper Jaffray CompaniesDowngradeOverweight ➝ NeutralN/A
i
Rating by joshua schimmer at Piper Jaffray Companies
11/15/2016Chardan CapitalReiterated RatingBuy$20.00 ➝ $12.00N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
8/29/2016SVB LeerinkReiterated RatingOutperform$27.00N/A
i
Rating by Michael Schmidt at SVB Leerink LLC
8/19/2016Piper Jaffray CompaniesSet Price TargetBuy$26.00 ➝ $16.00N/A
i
Rating by joshua schimmer at Piper Jaffray Companies
8/4/2016HC WainwrightInitiated CoverageBuy$21.00N/A
i
Rating by Mark Breidenbach at HC Wainwright
8/2/2016SVB LeerinkReiterated RatingPositive$27.00N/A
i
Rating by Michael Schmidt at SVB Leerink LLC
7/28/2016Jefferies Financial GroupSet Price TargetBuy$28.00N/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
7/28/2016Chardan CapitalSet Price TargetBuy$35.00N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
7/28/2016CowenReiterated RatingBuyN/A
i
Rating by Ritu Baral at Cowen Inc
7/18/2016Chardan CapitalReiterated RatingBuyN/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
6/30/2016Piper Jaffray CompaniesReiterated RatingBuyN/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
6/15/2016OppenheimerReiterated RatingOutperform$23.00N/A
i
Rating by Christopher Marai at Oppenheimer Holdings Inc.
6/15/2016WallachBeth CapitalLower Price TargetBuy$60.00 ➝ $35.00N/A
i
6/14/2016CowenReiterated RatingBuyN/A
i
Rating by Ritu Baral at Cowen Inc
6/13/2016Piper Jaffray CompaniesReiterated RatingBuyN/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
6/12/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Michael Schmidt at SVB Leerink LLC
6/2/2016CowenReiterated RatingBuyN/A
i
5/31/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
5/31/2016OppenheimerReiterated RatingBuyN/A
i
Rating by Christopher Marai at Oppenheimer Holdings Inc.
5/11/2016Chardan CapitalReiterated RatingBuy$35.00N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
4/14/2016Chardan CapitalReiterated RatingBuyN/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
4/13/2016SVB LeerinkReiterated RatingBuy$48.00 ➝ $27.00N/A
i
Rating by Michael Schmidt at SVB Leerink LLC
4/6/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
4/5/2016OppenheimerReiterated RatingBuy$50.00 ➝ $23.00N/A
i
Rating by Christopher Marai at Oppenheimer Holdings Inc.
4/5/2016Piper Jaffray CompaniesReiterated RatingOverweight$26.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
3/24/2016HC WainwrightReiterated RatingBuy$30.00N/A
i
3/23/2016Chardan CapitalReiterated RatingBuy$40.00N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
2/24/2016HC WainwrightReiterated RatingBuy$30.00N/A
i
Rating by Ching-Yi Lin at HC Wainwright
1/8/2016Janney Montgomery ScottReiterated RatingBuyN/A
i
Rating by Debjit Chattopadhyay at Janney Montgomery Scott
1/8/2016Chardan CapitalReiterated RatingBuy$40.00N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
1/8/2016Roth CapitalReiterated RatingBuy$37.00N/A
i
Rating by Debjit Chattopadhyay at Roth Capital
1/8/2016SVB LeerinkReiterated RatingOutperform$48.00N/A
i
1/8/2016OppenheimerReiterated RatingBuy$50.00N/A
i
Rating by Christopher Marai at Oppenheimer Holdings Inc.
1/6/2016Piper Jaffray CompaniesReiterated RatingOverweight$35.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
12/3/2015Jefferies Financial GroupReiterated RatingBuy$40.00 ➝ $36.00N/A
i
12/2/2015Chardan CapitalReiterated RatingBuy$40.00N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
12/1/2015OppenheimerReiterated RatingOutperform$50.00N/A
i
Rating by Christopher Marai at Oppenheimer Holdings Inc.
12/1/2015WallachBeth CapitalBoost Price TargetBuy$33.00 ➝ $60.00N/A
i
11/30/2015Janney Montgomery ScottInitiated CoverageBuy$40.00N/A
i
11/30/2015Piper Jaffray CompaniesReiterated RatingBuy$40.00 ➝ $35.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
11/30/2015CowenReiterated RatingBuyN/A
i
11/30/2015Roth CapitalInitiated CoverageBuy$37.00N/A
i
Rating by Debjit Chattopadhyay at Roth Capital
(Data available from 11/30/2015 forward)
uniQure logo
uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More

Today's Range

Now: $47.25
$46.91
$48.37

50 Day Range

MA: $41.20
$35.42
$46.50

52 Week Range

Now: $47.25
$34.38
$76.69

Volume

307,900 shs

Average Volume

467,490 shs

Market Capitalization

$2.10 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13